Wize Pharma Inc is a reputable company that upholds strong values and embodies a comprehensive corporate philosophy. With a steadfast commitment to excellence, Wize Pharma Inc prioritizes integrity, innovation, and accountability. This pharmaceutical company strives to deliver high-quality products and services to meet the ever-evolving needs of their customers. Through a continuous pursuit of knowledge and advancement, Wize Pharma Inc ensures the utmost satisfaction of their stakeholders. By incorporating ethical business practices and promoting transparency, this esteemed company establishes trust and credibility within the industry. Wize Pharma Inc remains dedicated to improving healthcare outcomes and enhancing the overall well-being of individuals worldwide.

Wize Pharma Inc is primarily present in the United States, Israel, and China.

Since its inception, Wize Pharma Inc has achieved several significant milestones. The company successfully developed and gained FDA approval for LO2A, its leading ophthalmic solution for the treatment of Dry Eye Syndrome (DES). In addition, Wize Pharma Inc established distribution agreements in various markets, expanding the global accessibility of LO2A. Furthermore, the company initiated clinical trials to evaluate LO2A's potential in treating other eye-related conditions. These achievements demonstrate Wize Pharma Inc's commitment to developing innovative solutions and expanding its presence in the ophthalmic market.

Wize Pharma Inc, founded in 1997, is a pharmaceutical company specializing in the development and commercialization of ophthalmic medications. Based in Israel, it focuses on innovative treatments for various ocular conditions, including dry eye syndrome. Wize Pharma Inc has a rich background of research and collaboration with renowned medical institutions to enhance its product portfolio. The company is dedicated to providing effective and safe solutions to improve eye health worldwide. With its commitment to research and development, Wize Pharma Inc continues to strive for advancements in ophthalmic therapeutics.

The main competitors of Wize Pharma Inc in the market include pharmaceutical companies such as Pfizer, Novartis, Johnson & Johnson, and Eli Lilly.

Wize Pharma Inc is primarily active in the healthcare industry.

Wize Pharma Inc is a pharmaceutical company that specializes in developing and commercializing ophthalmic medications. Their business model focuses on acquiring and licensing innovative ophthalmic drug products, conducting research and development, and seeking regulatory approvals. Wize Pharma Inc aims to meet the unmet medical needs in ophthalmology by improving existing therapeutic agents or developing new treatments for various eye disorders. Through strategic partnerships and collaborations, they strive to deliver cutting-edge solutions to the ophthalmic community and patients worldwide.

Wize Pharma에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

Wize Pharma에 대한 현재 KUV는 계산할 수 없습니다.

Wize Pharma에 대한 AlleAktien 품질 점수는 5/10입니다.

Wize Pharma에 대한 현재 매출은 계산할 수 없습니다.

Wize Pharma의 현재 이익을 계산할 수 없습니다.

Wize Pharma Inc is a company specialized in the development and marketing of medications. It focuses on eye diseases such as cataract, dry eye, and certain corneal diseases. The company is headquartered in Israel and is listed on the Tel Aviv Stock Exchange. Wize Pharma's business model is based on three main aspects: research, development, and marketing. The research department develops new active substances and technologies to find targeted therapeutic solutions for eye diseases. The development department is responsible for manufacturing active substances and medications based on the research results. Finally, marketing is done through the distribution of medications to doctors and pharmacies, as well as collaboration with partner companies. One of Wize Pharma's key products is the medication LO2A. It was specifically developed for the treatment of cataract and is approved in several countries, including Israel, the USA, and Canada. What makes LO2A unique is that it contains a natural substance called lanosterol, which studies have shown can prevent the formation of cataracts in the eyes. Another product in Wize Pharma's portfolio is the medication PLxGuard. It was developed specifically for the treatment of dry eye and contains Omega-3 fatty acids and Vitamin E, among other ingredients. PLxGuard is also approved in some countries and is marketed through the company's own distribution channel and partner companies. Wize Pharma emphasizes high quality and intensive collaboration with doctors and pharmacies in the marketing of its products. Regular training and continuing education are provided to healthcare professionals to keep them informed about the latest developments in the field of ophthalmology, enabling them to recommend the best possible therapy to their patients. Wize Pharma also maintains high quality standards and transparency in its collaboration with partner companies. Overall, Wize Pharma's business model is characterized by high innovation and a clear focus on the needs of patients with eye diseases. With the combination of research, development, and marketing, the company is well-positioned to continue its success and contribute to improving the health and quality of life for people with eye diseases.

Wize Pharma은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Wize Pharma의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Wize Pharma의 ISIN은 US97751M2070입니다.

Wize Pharma의 티커는 WIZP입니다.

지난 12개월 동안 Wize Pharma은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Wize Pharma은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Wize Pharma의 현재 배당 수익률은 입니다.

Wize Pharma은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Wize Pharma은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Wize Pharma은 '건강' 섹터에 속합니다.

Wize Pharma의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Wize Pharma는 0 USD를 배당금으로 지급했습니다.

Wize Pharma의 배당금은 USD에 지급됩니다.